JUBILANT LIFE SCIENCES LIMITED - 530019 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Jubilant Life Sciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Dear Sirs, The 42nd Annual General Meeting ('AGM') of Jubilant Life Sciences Limited ('the Company') has been held today i.e. Friday, September 11, 2020 at 10.00 a.m. through Video Conferencing/ Other Audio Visual Means. We submit the Consolidated Scrutinizer''s Report pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014. We request you to take the same on record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Intimation under Regulation 30 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sirs, The 42nd Annual General Meeting ('AGM') of Jubilant Life Sciences Limited ('the Company') has been held today i.e. Friday, September 11, 2020 at 10.00 a.m. through Video Conferencing/ Other Audio Visual Means. Pursuant to Regulation 30 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'SEBI Listing Regulations') we submit the following: 1.Proceedings of the 42nd AGM of the Company - Annexure 1. 2.Voting results of the AGM pursuant to Regulation 44 of the SEBI Listing Regulations - Annexure 2. 3.Consolidated Scrutinizer''s Report pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 - Annexure 3. We request you to take the same on records. Earnings Call Transcript - Q1FY21 for Jubilant Life Sciences
Conference Call with Jubilant Life Sciences Management and Analysts on Q1FY21 Performance and Outlook. Click on pdf to read the full text transcript.
Buy Jubilant Life Sciences; target of Rs 975: Motilal Oswal
Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 05, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Sub.: Submission of copies of published Unaudited Consolidated Financial Results In continuation of our letter dated September 4, 2020, we enclose the copies of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2020 published on September 5, 2020 in MINT (English) and HINDUSTAN (Hindi). This is for information and records. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Mr. Alok Vaish, Chief Financial Officer and Key Managerial Personnel, has tendered his resignation from services of the Company which has been accepted by the Company. He shall continue in his current role until September 11, 2020. We request you to take the same on record.
Earnings Call Transcript - Q1FY21 for Jubilant Life Sciences
Conference Call with Jubilant Life Sciences Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript.
Jubilant Life Sciences Q1 net profit declines 52% to 88 crore
The company had posted a net profit of 184.98 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said JUBILANT LIFE SCIENCES LIMITED - 530019 - Results For The Quarter Ended June 30, 2020
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2020 were approved by the Board of Directors of the Company at its meeting held today at 1:00 p.m. and concluded at 3.30 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2020; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records.